Rock Creek Pharmaceuticals Inc is a United States-based pharmaceutical development company. The Company is focused on the discovery, development and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its activities are focused on its lead compound, anatabine citrate (anatabine). Anatabine is a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics. The Company focuses on dermatological skin diseases, such as psoriasis, eczema and rare or orphan skin disorders, using its formulations of anatabine.

Employees

Sector

Pharmaceuticals

More about the company

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

20-12-07	Rock Creek Pharmaceuticals, Inc. Went Out of Business	CI
20-02-05	Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc.	CI

Market Cap	153K 134K 123K 116K 217K 14.46M 218K 1.47M 569K 7.12M 576K 563K 24.69M	P/E 2014	-0.87x	P/E 2015	-1.04x
Enterprise Value	20.01M 17.44M 16.07M 15.12M 28.28M 1.89B 28.48M 191M 74.26M 929M 75.11M 73.5M 3.22B	EV / Sales 2014	-	EV / Sales 2015	-
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

20-12-07	Rock Creek Pharmaceuticals, Inc. Went Out of Business	CI
20-02-05	Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc.	CI
18-12-20	Motion for Asset Sale Filed by Rock Creek Pharmaceuticals, Inc.	CI
18-01-10	Motion for Asset Sale Approved for Rock Creek Pharmaceuticals, Inc.	CI
16-09-27	Rock Creek Pharmaceuticals, Inc. Filed for Bankruptcy	CI
16-08-29	Rock Creek Pharmaceuticals, Inc. Receives Event of Default Redemption Notice from Hudson Bay Master Fund Ltd. and from Tenor Capital Management on Behalf of Alto Opportunity Master Fund	CI
16-08-10	Rock Creek Pharmaceuticals, Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2016	CI
16-07-08	Rock Creek Pharmaceuticals, Inc. Announces Board Changes	CI
16-06-08	Rock Creek Pharmaceuticals, Inc. Reports Earnings results for the First Quarter Ended March 31, 2016	CI
16-03-29	Rock Creek Pharmaceuticals, Inc. announced that it has received $0.5 million in funding.	CI
16-03-22	Rock Creek Pharmaceuticals, Inc. Announces Earnings Results for the Year Ended December 31, 2015	CI
16-03-21	Rock Creek Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
15-11-19	Rock Creek Pharmaceuticals, Inc. Appoints Robert Scannell as Director	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ROCK CREEK PHARMACEUTICALS, INC.	-.--%	-.--%	-	-	17.04K
ELI LILLY AND COMPANY	-1.21%	-5.37%	+39.94%	+145.38%	992B
JOHNSON & JOHNSON	-2.48%	-4.17%	+51.52%	+39.07%	564B
ABBVIE INC.	-2.14%	-3.68%	+16.71%	+56.15%	391B
ROCHE HOLDING AG	-1.18%	+0.68%	+24.66%	+16.53%	330B
ASTRAZENECA PLC	-2.36%	-2.30%	+23.37%	+11.59%	280B
NOVARTIS AG	-2.45%	-0.84%	+23.51%	+30.06%	279B
NOVO NORDISK A/S	-1.91%	-1.06%	-42.60%	-49.25%	196B
AMGEN INC.	-1.19%	-4.65%	+16.56%	+47.00%	184B
GILEAD SCIENCES, INC.	-1.35%	-1.68%	+14.59%	+56.94%	156B
Average	-1.63%	-0.39%	+18.70%	+39.27%	337.12B
Weighted average by Cap.	-1.77%	-2.07%	+27.70%	+63.21%

Rock Creek Pharmaceuticals, Inc. Stock

Stocks

RCPIQ

US7720812046

Pharmaceuticals

Valuation: Rock Creek Pharmaceuticals, Inc.

Latest news : Rock Creek Pharmaceuticals, Inc.

Analysts' recommendations: Rock Creek Pharmaceuticals, Inc.

Other Pharmaceuticals

Financials

Company Profile

	2014	2015
Net sales	-	-
Net income	-38.52M -33.56M -30.94M -29.1M -54.44M -3.63B -54.82M -368M -143M -1.79B -145M -141M -6.2B	-6.84M -5.96M -5.5M -5.17M -9.67M -645M -9.74M -65.41M -25.4M -318M -25.69M -25.14M -1.1B
Net Debt	-45K -39.21K -36.14K -34K -63.6K -4.24M -64.05K -430K -167K -2.09M -169K -165K -7.24M	19.86M 17.3M 15.95M 15M 28.07M 1.87B 28.26M 190M 73.69M 922M 74.53M 72.94M 3.2B